Boundless Bio, Inc. (BOLD) is a clinical-stage oncology company developing therapies that target extrachromosomal DNA (ecDNA) in oncogene-amplified cancers. Its sell-side coverage is thin, reflecting its small size and pre-revenue stage. Two current, verifiable targets anchor the $4 figure used in this analysis: H.C. Wainwright reiterated a Buy with a $4 target in August 2025 (lowered from $5), and Leerink Partners reiterated a Market Perform rating with a $4 target in March 2026 after the company's fourth-quarter 2025 results and pipeline update.
Because both current targets sit at $4, the arithmetic mean is $4. Over the past year, targets have ranged from $3 to $5. Notably, Leerink downgraded the stock from Outperform to Market Perform in May 2025 and cut its target sharply from $15 to $3, and Guggenheim moved from Buy to Neutral in late 2024 without a published target. Much higher figures from the 2024 IPO — such as $20 (Piper Sandler) and $24–$25 (Guggenheim and Leerink) — are stale and are not included. The takeaway is a divided, cautious-to-moderately-bullish view: analysts see upside potential, but no firm is aggressive about it.
At a recent price near $2.41, with a market capitalization in the tens of millions of dollars, BOLD trades well below its 52-week high of about $3.16 and above its 52-week low of roughly $0.96. Reaching $4 would require an upside of approximately 66%, which qualifies as a very large move for a stock at this stage of development.
The path would depend almost entirely on clinical execution rather than earnings. Boundless Bio has begun enrollment in KOMODO-1, a Phase 1 dose-escalation and dose-expansion study of BBI-940, an oral kinesin degrader, in ER+/HER2- breast cancer and triple-negative breast cancer. Management expects to deliver proof-of-concept data within a cash runway extending into the second half of 2028. The company ended 2025 with roughly $108 million in cash, and its Q4 2025 loss of $0.58 per share was narrower than the consensus estimate of a $1.16 loss.
BOLD's 52-week range of roughly $0.96 to $3.16 frames its recent trading. The $3.16 prior high stands as a meaningful resistance zone, and $4 sits well above that level, making it a psychological target rather than a nearby technical objective. On the downside, the area near $1.00 to $1.15 has acted as support during the stock's weakest periods. A sustained move toward $4 would require a decisive break above the prior high — a level the stock has not yet proven it can hold.
Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms may differ, and for a clinical-stage company the relevant timeline is really driven by data readouts rather than the calendar. Investors should monitor KOMODO-1 enrollment and any interim data, quarterly cash-burn figures and balance-sheet updates, changes to the cash runway, and any analyst rating or target revisions. Company guidance on the timing of proof-of-concept data for BBI-940 is the single most important catalyst to the $4 question.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile micro-cap like BOLD, such tools can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual scanning. Traders interested in systematic, data-driven monitoring can explore these signals as a complement to their own research.
Can Boundless Bio stock reach $4? The target — the average of two current analyst price targets, both at $4 — is credible as a 12-month objective but requires a very large advance of roughly 66% from recent levels. The bull case rests squarely on successful execution of the BBI-940 KOMODO-1 program and proof-of-concept data within a cash runway extending to 2028. The bear case points to a single-asset pipeline, the 2026 discontinuation of two earlier candidates, and the inherent risk of clinical-stage oncology investing. With analyst targets ranging from $3 to $5 in the past year and no aggressive conviction behind the stock, the path to $4 is possible but far from assured. Investors should watch KOMODO-1 data, cash burn, and analyst revisions before drawing any conclusion.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that BOLD and DNA have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BOLD and DNA's prices will move in lockstep.
| Ticker / NAME | Correlation To BOLD | 1D Price Change % | ||
|---|---|---|---|---|
| BOLD | 100% | -0.41% | ||
| DNA - BOLD | 32% Poorly correlated | -2.91% | ||
| RXRX - BOLD | 31% Poorly correlated | -6.70% | ||
| PRTA - BOLD | 30% Poorly correlated | -2.45% | ||
| EWTX - BOLD | 29% Poorly correlated | -4.53% | ||
| VYGR - BOLD | 29% Poorly correlated | -8.29% | ||
More | ||||